Log in
(Ad)
A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

NASDAQ:REPH - Recro Pharma Stock Price, Forecast & News

$16.10
-0.16 (-0.98 %)
(As of 01/20/2020 01:43 AM ET)
Today's Range
$15.93
Now: $16.10
$16.47
50-Day Range
$16.10
MA: $17.09
$18.82
52-Week Range
$5.53
Now: $16.10
$19.00
Volume205,391 shs
Average Volume299,874 shs
Market Capitalization$365.95 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.34
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPH
CUSIPN/A
Phone484-395-2470

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$77.35 million
Book Value($0.91) per share

Profitability

Net Income$-79,720,000.00

Miscellaneous

Employees255
Market Cap$365.95 million
Next Earnings Date2/18/2020 (Estimated)
OptionableOptionable

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


Investors looking for the best way to potentially double their money in 2020 -- regardless of whether the overall markets are up or down -- should look no further than these 3 unique stocks.

This Special Report reveals the names of these stocks and provides everything you need to invest right away.

Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

How were Recro Pharma's earnings last quarter?

Recro Pharma Inc (NASDAQ:REPH) released its earnings results on Friday, November, 8th. The specialty pharmaceutical company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.06. The specialty pharmaceutical company had revenue of $25.26 million for the quarter, compared to analyst estimates of $19.83 million. View Recro Pharma's Earnings History.

When is Recro Pharma's next earnings date?

Recro Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Recro Pharma.

What guidance has Recro Pharma issued on next quarter's earnings?

Recro Pharma updated its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $$98-100 million, compared to the consensus revenue estimate of $$95.52 million.

What price target have analysts set for REPH?

4 Wall Street analysts have issued 1 year price targets for Recro Pharma's shares. Their forecasts range from $7.50 to $20.00. On average, they anticipate Recro Pharma's stock price to reach $14.88 in the next year. This suggests that the stock has a possible downside of 7.6%. View Analyst Price Targets for Recro Pharma.

What is the consensus analysts' recommendation for Recro Pharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Recro Pharma.

Has Recro Pharma been receiving favorable news coverage?

Press coverage about REPH stock has been trending positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Recro Pharma earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Recro Pharma.

Are investors shorting Recro Pharma?

Recro Pharma saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,290,000 shares, an increase of 20.6% from the December 15th total of 1,070,000 shares. Based on an average trading volume of 315,200 shares, the short-interest ratio is currently 4.1 days. Currently, 6.7% of the shares of the stock are sold short. View Recro Pharma's Current Options Chain.

Who are some of Recro Pharma's key competitors?

What other stocks do shareholders of Recro Pharma own?

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the folowing people:
  • Dr. Geraldine A. Henwood, Pres, CEO & Director (Age 67)
  • Mr. Ryan D. Lake, Chief Financial Officer (Age 42)
  • Mr. Michael Celano, COO & Corp. Sec. (Age 60)
  • Mr. Randall J. Mack, Sr. VP of Devel. & Corp. Sec. (Age 54)
  • Ms. Diane Myers, Sr. VP of Regulatory Affairs & Quality Assurance (Age 55)

Who are Recro Pharma's major shareholders?

Recro Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Calamos Advisors LLC (0.74%) and Wedge Capital Management L L P NC (0.62%). Company insiders that own Recro Pharma stock include Arnaud Ajdler, Geraldine Henwood and Healthcare Master Fun Broadfin. View Institutional Ownership Trends for Recro Pharma.

Which institutional investors are buying Recro Pharma stock?

REPH stock was acquired by a variety of institutional investors in the last quarter, including Calamos Advisors LLC and Wedge Capital Management L L P NC. View Insider Buying and Selling for Recro Pharma.

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $16.10.

How big of a company is Recro Pharma?

Recro Pharma has a market capitalization of $365.95 million and generates $77.35 million in revenue each year. The specialty pharmaceutical company earns $-79,720,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Recro Pharma employs 255 workers across the globe.View Additional Information About Recro Pharma.

What is Recro Pharma's official website?

The official website for Recro Pharma is http://www.recropharma.com/.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]


MarketBeat Community Rating for Recro Pharma (NASDAQ REPH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  317 (Vote Outperform)
Underperform Votes:  273 (Vote Underperform)
Total Votes:  590
MarketBeat's community ratings are surveys of what our community members think about Recro Pharma and other stocks. Vote "Outperform" if you believe REPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel